Drugs in R and D : Impact Factor & More
eISSN: 1179-6901pISSN: 1174-5886
Open AccessShare this on:
Key Metrics
CiteScore 
4.3
Impact Factor
< 5
SJR
Q2Pharmacology
SNIP
0.95
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Drugs in R and D
Drugs in R and D Journal Specifications
| Overview | |
| Publisher | SPRINGER INT PUBL AG |
| Language | English |
| Frequency | Quarterly |
| Article Processing Charges | EUR 2690 | USD 3390 | GBP 2290 |
| Publication Time | 8 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 1999 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Drugs in R and D ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Drugs in R and D
Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
- 1 Jun 2026
- Drugs in R&D
Optimizing Drug-Resistant Epilepsy Management: Cenobamate\u2019s role in the Surgery/Neuromodulation Pathway
- 1 Jun 2026
- Drugs in R&D
Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
- 1 Jun 2026
- Drugs in R&D
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
- 24 May 2026
- Drugs in R&D
Ustekinumab in the Management of Perianal Fistulizing Crohn\u2019s Disease: Current Evidence and Practical Strategies
- 22 May 2026
- Drugs in R&D
HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.
- 3 Apr 2026
- Drugs in R&D
Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
- 1 Jun 2026
- Drugs in R&D
Optimizing Drug-Resistant Epilepsy Management: Cenobamate\u2019s role in the Surgery/Neuromodulation Pathway
- 1 Jun 2026
- Drugs in R&D
Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
- 1 Jun 2026
- Drugs in R&D
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
- 24 May 2026
- Drugs in R&D
Ustekinumab in the Management of Perianal Fistulizing Crohn\u2019s Disease: Current Evidence and Practical Strategies
- 22 May 2026
- Drugs in R&D
HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance.
- 3 Apr 2026
- Drugs in R&D
FAQs on Drugs in R and D
How long has Drugs in R and D been actively publishing? 
What is the publishing frequency of Drugs in R and D?
How many articles did Drugs in R and D publish last year?
What is the eISSN & pISSN for Drugs in R and D?
What is Citescore for Drugs in R and D?
What is SNIP score for Drugs in R and D?
What is the SJR for Drugs in R and D?
Who is the publisher of Drugs in R and D?
